News
Le Document d’Enregistrement Universel 2024 de GENFIT comprend notamment : Le rapport du conseil d’administration sur le gouvernement d’entreprise, Les rapports des contrôleurs légaux des comptes sur ...
GENFIT’s 2024 Universal Registration Document includes, in particular : The Statutory Auditors’ reports on the annual and consolidated financial statements and related-party agreements, The table ...
SAN JOSE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative ...
First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE ...
Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro de spécialité, annonce avoir mis à disposition du public et déposé auprès de ...
The Phase 3 ABTECT trials (Studies 105 and 106) evaluating obefazimod in patients with moderately to severely active ulcerative colitis successfully enrolled 1,275 participants, exceeding the target ...
About CooperCompanies CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, ...
This exclusive private label distribution agreement with Smith+Nephew is a significant development for Nuo ,” commented David Jorden, Nuo’s Chief Executive and Financial Officer. “ We could not ...
Conference Call and Webcast scheduled for tomorrow, April 30, 2025 at 10:00 am PT. SAN JUAN CAPISTRANO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ...
Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable ...
DUBLIN and BRIDGEWATER, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced it has regained compliance with the Nasdaq Stock Market (“Nasdaq”) continued ...
Commercial Progress: The first full quarter of Attruby net product revenue was $36.7 million. As of April 25, 2025, 2,072 unique patient prescriptions for Attruby have been written by 756 unique ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results